Novo Nordisk Rebrands to Novo as Obesity Becomes a Consumer Market

The Novo Nordisk rebrand announced on 14 September 2026 is a brand and culture reset, not a sale, spin-off, or legal name change. Day to day the company will trade as a single name, Novo, under the line “Lasting Health Starts Now,” with a new operating code called The Novo Way. The legal entity remains Novo Nordisk A/S, and the strategy numbers everyone is waiting for land at Capital Markets Day in London on 21 September 2026.

The rebrand is a signal, not a strategy. Novo is betting that obesity no longer behaves like classic chronic-care pharma and now behaves like consumer health, where people start and stop therapy the way they change phone plans. CEO Mike Doustdar, in the role since 2025, has said the identity change and the culture reset are part of the same package.

What changes and what stays

The everyday name drops “Nordisk.” It now trades as Novo, the Latin word for “new” and the original 1920s house name. The full legal name, Novo Nordisk A/S, dates to the 1989 merger of Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium, and it stays in place worldwide. The pattern matches GSK and Sanofi, and it sits close to Lilly dropping “Eli” from its marketing.

Ad

The visual identity keeps the Apis bull, in use since the 1920s, but modernises it. The bull now faces right, a deliberate “looking forward” cue. The palette is Lasting Blue with an accent called Now Turquoise, and the new typeface is simply called Novo.

The Novo Way

The culture code shrinks from the old ten Essentials to four principles: Customer Obsession, Competitiveness, Clarity, and Care and Integrity.

The first principle is the telling one. The earlier code, written under Lars Rebien Sørensen, put the patient at the centre. The new language says “consumers and patients.” Danish coverage picked up on that shift from “patient” to “customer,” the clearest signal in the package about where Novo believes the market has moved.

Why the timing matters

The rebrand lands one week before Capital Markets Day, and Doustdar frames it as the wrapper for a wider rethink across R&D, manufacturing, sales, and marketing. His argument is that obesity is a multi-brand category, not a two-horse race, and that Novo should compete with a portfolio rather than a single injectable: injectable and oral Wegovy, CagriSema, zenagamtide, cagrilintide, and direct-to-patient rails through NovoCare and retail partners. He calls the company a “cardiometabolic powerhouse,” not a one-drug house.

What they leave behind

The dual name is gone from daily use, along with the old culture code, the patient-only language, and the 2024 story of uncontested GLP-1 leadership. The stock has fallen roughly 15% year to date, Lilly has taken the obesity crown, and 2026 guidance points to 0% to -6% adjusted sales and operating profit at constant exchange rates. Semaglutide is still about 75% of sales, and it already loses exclusivity in parts of International Operations, with a larger US and EU cliff in the early 2030s. Last week the company stopped two more late-stage ziltivekimab heart failure trials after the ZEUS miss.

What the Novo Nordisk rebrand means for market access

The name now points the same way as the channel. Oral Wegovy, NovoCare, and retail and telehealth deals need a brand that works on a phone screen, and “Lasting Health Starts Now” is built for that. The move toward direct-to-consumer pharmaceutical access is where Novo and Lilly have been competing hardest, and the identity now matches that reality.

The risk is that a logo does not recover share or a patent cliff. Morgan Stanley cut the stock to Underweight this month on mid-term growth and loss of exclusivity, and it models semaglutide at about 59% of sales in 2031. Novo already faces US list-price cuts of roughly 50% on Wegovy and 35% on Ozempic from 1 January 2027. A rebrand cannot answer those numbers on its own.

There is also a cost. A global identity rollout across packaging, sites, exhibits, and HCP materials spends money in a year already guided to flat or down sales. And “customer obsession” is a break from a century of insulin-as-duty language, which some staff may read as a tilt from stewardship to performance culture.

What to watch

The announcement is the wrapper. The test is Capital Markets Day on 21 September, where Novo has to show a path through the price cuts, the semaglutide cliff, Lilly, and a pipeline that just lost its best near-term shot outside obesity.

Source: Novo Nordisk press release, 14 September 2026.